|
|
|
|
|
|
|
¸ñÂ÷ |
|
Double pulmonary nodules.- Nodular sclerosing Hodgkin?s lymphoma.- Transformation in non-Hodgkin?s lymphoma.- Metabolic phenotypes in different neoplasms.- Marrow involvement in non-Hodgkin?s lymphoma.- Hip pain in lymphoma.- Prostate cancer specific PET agent with rising PSA.- Brain tumor evaluation.- Metabolic phenotypes in slowly growing lung cancers.- Metabolic phenotypes in lung metastasis from colon cancer.- PET and bone scan in non-small cell lung cancer (NSCLC).- Neuroendocrine cancer of ileum.- Coexisting different PET tumor phenotypes.- COVID vaccination and lung nodules.- COVID vaccination and tumor phenotypes.- Breast and ovarian uptake.- Rising PSA in radical prostatectomy for prostate cancer.- Concurrent lung and brain metastatic cancer.- Tumor phenotypes in metastatic prostate cancer.- Metastatic recurrent melanoma.- Post-prostatectomy for prostate cancer with rising PSA.- Left adrenal mass.- Cutaneous T-cell lymphoma.- Active myeloma versus Schmorl?s node.- Small cell lung cancer.- Synchronous PEComa and lung adenocarcinoma.- Breast cancer after immunochemotherapy.- Squamous cell lung cancer.- Lymphoma and breast cancer.- Prostate cancer.- Neurofibromatosis and cerebellar encephalomalacia.- Mucinous Colonic Adenocarcinoma.- Poorly differentiated gastric cancer with signet-ring cell features.- Granulomatosis disease involving lung, lymph nodes, and multiple bones.- Lung nodules in esophageal cancer.- Squamous cell cancer (SCC) of neck.- Metastatic prostate adenocarcinoma.- Mesothelioma.- Recurrent papillary thyroid carcinoma.- Newly diagnosed prostate adenocarcinoma.- Alveolar rhabdomyosarcoma with a favorable response to chemoradiation.- CNS post-transplant lymphoproliferative disease.- Solitary plasmacytoma.- Parotid oncocytic carcinoma.- Pelvic sarcoma with IVC metastatic thrombus.- Diffuse muscle uptake and vigorous exercise.- Post-excision residual urothelial carcinoma.- Phenotypic pattern of Erdheim-Chester disease (ECD).- Different metabolic phenotypes in renal clear cell cancer and cervix cancer.- Bladder adenocarcinoma with chemoresistance.- Wax-and-wane metabolic activities of low-grade lymphoma.- Reactive adenopathy in treated classic Hodgkin?s lymphoma.- Chemo-refractory diffuse large B cell lymphoma (DLBCL).- Primary cutaneous DLBCL, leg type (PC-DLBCL LT).- Primary pulmonary MALT lymphoma.- Concurrent low-grade follicular lymphoma (LG FL) and DLBCL.- Primary bone lymphoma (PBL).- Lymphomatoid granulomatosis (LYG) variant of DLBCL.- Secondary central nervous system lymphoma (SCNSL).- Complete discordant PET in pathologically diagnosed low grade lymphoma.- Transplant-related B-cell lymphoma.- Bone lesions in primary breast lymphoma.- Recurrent gastrointestinal stromal tumor (GIST) with necrosis.- Peritoneal mesothelioma.- Cutaneous Kaposi sarcoma.- FDG-avid and non-FDG-avid multiple myeloma (MM).- Advanced pancreatic cancer with abdominopelvic carcinomatosis.- Advanced breast cancer with extensive bone metastases.- Concurrent lung cancer and endocervix cancer.- Inflammatory breast cancer.- Recurrent high-grade urothelial carcinoma.- Primary thyroid lymphoma (PTL).- High-grade tonsillar large B-cell lymphoma.- Phenotypic pattern of primary renal DLBCL with double expressor.- Recurrent primary colonic lymphoma (PCL).- Maxillofacial extra nodal marginal zone malignant B-cell lymphoma.- Primary dural lymphoma with leptomeningeal involvement.- Primary CNS lymphoma (PCNSL).- Primary gastric lymphoma.- Residual primary prostate lymphoma.- PET SuperScan.- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH).- Metastatic ovarian carcinoma.- Metastatic prostate cancer or neuroendocrine tumor?.- Metastatic thyroid carcinoma.- Primary invasive ductal breast cancer or metastatic neuroendocrine cancer?.- Atypical oligo-metastasis of malignant melanoma.- Dual-time PET CT evaluation of lung nodules.- Phenotypic pattern of combined large cell neuroendocrine cancer and SCC.- Primary pulmonary amyloidosis.- Advanced follicular dentritic cell sarcoma.- Oligometastatic prostate cancer.- Bulky primary mediastinal non-Hodgkin?s lymphoma.- Pulmonary sarcoid or recurrent lung adenocarcinoma?.- Oligo- or multiple bone metastases in newly diagnosed prostate cancer.- Reactive lymph nodes and granulomas associated with breast implant rupture.- Metabolic phenotypes of anaplastic thyroid carcinoma and metastases.- Male breast carcinoma.- Advanced HCC featured by IVC/right atrium tumor thrombus.- Phenotypes of lung cancer and pulmonary lymphangitic carcinomatosis. |
|
|
|
|
|
|
|
Ãâ°í¾È³» |
|
|
Ãâ°í¶õ ÀÎÅÍÆÄÅ© ¹°·ùâ°í¿¡¼ µµ¼°¡ Æ÷ÀåµÇ¾î ³ª°¡´Â ½ÃÁ¡À» ¸»Çϸç, ½ÇÁ¦ °í°´´Ô²²¼ ¼ö·ÉÇϽô ½Ã°£Àº »óÇ°Áغñ¿Ï·áÇØ Ãâ°íÇÑ ³¯Â¥ + Åùè»ç ¹è¼ÛÀÏÀÔ´Ï´Ù. |
|
ÀÎÅÍÆÄÅ© µµ¼´Â ¸ðµç »óÇ°ÀÇ Àç°í°¡ ÃæÁ·ÇÒ ½Ã¿¡ ÀÏ°ý Ãâ°í¸¦ ÇÕ´Ï´Ù. |
|
ÀϺΠÀç°í¿¡ ´ëÇÑ Ãâ°í°¡ ÇÊ¿äÇÒ ½Ã¿¡´Â ´ã´çÀÚ¿¡°Ô Á÷Á¢ ¿¬¶ôÇϽðųª, °í°´¼¾ÅÍ(°í°´¼¾ÅÍ(1577-2555)·Î ¿¬¶ôÁֽñ⠹ٶø´Ï´Ù. |
|
¹è¼Ûºñ ¾È³» |
|
|
ÀÎÅÍÆÄÅ© µµ¼ ´ë·®±¸¸Å´Â ¹è¼Û·á°¡ ¹«·áÀÔ´Ï´Ù. |
|
´Ü, 1°³ÀÇ »óÇ°À» ´Ù¼öÀÇ ¹è¼ÛÁö·Î ÀÏ°ý ¹ß¼Û½Ã¿¡´Â 1°³ÀÇ ¹è¼ÛÁö´ç 2,000¿øÀÇ ¹è¼Ûºñ°¡ ºÎ°úµË´Ï´Ù. |
¾Ë¾ÆµÎ¼¼¿ä! |
|
|
°í°´´Ô²²¼ ÁÖ¹®ÇϽŠµµ¼¶óµµ µµ¸Å»ó ¹× ÃâÆÇ»ç »çÁ¤¿¡ µû¶ó Ç°Àý/ÀýÆÇ µîÀÇ »çÀ¯·Î Ãë¼ÒµÉ ¼ö ÀÖ½À´Ï´Ù. |
|
Åùè»ç ¹è¼ÛÀÏÀÎ ¼¿ï ¹× ¼öµµ±ÇÀº 1~2ÀÏ, Áö¹æÀº 2~3ÀÏ, µµ¼, »ê°£, ±ººÎ´ë´Â 3ÀÏ ÀÌ»óÀÇ ½Ã°£ÀÌ ¼Ò¿äµË´Ï´Ù.
(´Ü, Åä/ÀÏ¿äÀÏ Á¦¿Ü) |
|
|
|
|
ÀÎÅÍÆÄÅ©µµ¼´Â °í°´´ÔÀÇ ´Ü¼ø º¯½É¿¡ ÀÇÇÑ ±³È¯°ú ¹ÝÇ°¿¡ µå´Â ºñ¿ëÀº °í°´´ÔÀÌ ÁöºÒÄÉ µË´Ï´Ù.
´Ü, »óÇ°À̳ª ¼ºñ½º ÀÚüÀÇ ÇÏÀÚ·Î ÀÎÇÑ ±³È¯ ¹× ¹ÝÇ°Àº ¹«·á·Î ¹ÝÇ° µË´Ï´Ù.
±³È¯/¹ÝÇ°/º¸ÁõÁ¶°Ç ¹× Ç°Áúº¸Áõ ±âÁØÀº ¼ÒºñÀڱ⺻¹ý¿¡ µû¸¥ ¼ÒºñÀÚ ºÐÀï ÇØ°á ±âÁØ¿¡ µû¶ó ÇÇÇظ¦ º¸»ó ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.
Á¤È®ÇÑ È¯ºÒ ¹æ¹ý ¹× ȯºÒÀÌ Áö¿¬µÉ °æ¿ì 1:1¹®ÀÇ °Ô½ÃÆÇ ¶Ç´Â °í°´¼¾ÅÍ(1577-2555)·Î ¿¬¶ô Áֽñ⠹ٶø´Ï´Ù.
¼ÒºñÀÚ ÇÇÇغ¸»óÀÇ ºÐÀïó¸® µî¿¡ °üÇÑ »çÇ×Àº ¼ÒºñÀÚºÐÀïÇØ°á±âÁØ(°øÁ¤°Å·¡À§¿øȸ °í½Ã)¿¡ µû¶ó ºñÇØ º¸»ó ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.
|
±³È¯ ¹× ¹ÝÇ°ÀÌ °¡´ÉÇÑ °æ¿ì |
|
|
»óÇ°À» °ø±Þ ¹ÞÀ¸½Å ³¯·ÎºÎÅÍ 7ÀÏÀ̳» °¡´ÉÇÕ´Ï´Ù. |
|
°ø±Þ¹ÞÀ¸½Å »óÇ°ÀÇ ³»¿ëÀÌ Ç¥½Ã, ±¤°í ³»¿ë°ú ´Ù¸£°Å³ª ´Ù¸£°Ô ÀÌÇàµÈ °æ¿ì¿¡´Â °ø±Þ¹ÞÀº ³¯·ÎºÎÅÍ 3°³¿ùÀ̳», ±×»ç½ÇÀ» ¾Ë°Ô µÈ ³¯ ¶Ç´Â ¾Ë ¼ö ÀÖ¾ú´ø ³¯·ÎºÎÅÍ 30ÀÏÀ̳» °¡´ÉÇÕ´Ï´Ù. |
|
»óÇ°¿¡ ¾Æ¹«·± ÇÏÀÚ°¡ ¾ø´Â °æ¿ì ¼ÒºñÀÚÀÇ °í°´º¯½É¿¡ ÀÇÇÑ ±³È¯Àº »óÇ°ÀÇ Æ÷Àå»óÅ µîÀÌ ÀüÇô ¼Õ»óµÇÁö ¾ÊÀº °æ¿ì¿¡ ÇÑÇÏ¿© °¡´ÉÇÕ´Ï´Ù.
|
|
|
|
±³È¯ ¹× ¹ÝÇ°ÀÌ ºÒ°¡´ÉÇÑ °æ¿ì |
|
|
|
°í°´´ÔÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óÇ° µîÀÌ ¸ê½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì´Â ºÒ°¡´ÉÇÕ´Ï´Ù. (´Ü, »óÇ°ÀÇ ³»¿ëÀ» È®ÀÎÇϱâ À§ÇÏ¿© Æ÷Àå µîÀ» ÈѼÕÇÑ °æ¿ì´Â Á¦¿Ü) |
|
½Ã°£ÀÌ Áö³²¿¡ µû¶ó ÀçÆǸŰ¡ °ï¶õÇÒ Á¤µµ·Î ¹°Ç°ÀÇ °¡Ä¡°¡ ¶³¾îÁø °æ¿ì´Â ºÒ°¡´ÉÇÕ´Ï´Ù. |
|
Æ÷Àå °³ºÀµÇ¾î »óÇ° °¡Ä¡°¡ ÈÑ¼ÕµÈ °æ¿ì´Â ºÒ°¡´ÉÇÕ´Ï´Ù. |
|
|
´Ù¹è¼ÛÁöÀÇ °æ¿ì ¹ÝÇ° ȯºÒ |
|
|
|
´Ù¹è¼ÛÁöÀÇ °æ¿ì ´Ù¸¥ Áö¿ªÀÇ ¹ÝÇ°À» µ¿½Ã¿¡ ÁøÇàÇÒ ¼ö ¾ø½À´Ï´Ù. |
|
1°³ Áö¿ªÀÇ ¹ÝÇ°ÀÌ ¿Ï·áµÈ ÈÄ ´Ù¸¥ Áö¿ª ¹ÝÇ°À» ÁøÇàÇÒ ¼ö ÀÖÀ¸¹Ç·Î, ÀÌÁ¡ ¾çÇØÇØ Áֽñ⠹ٶø´Ï´Ù. |
|
|
|
|
|
|